Navigation Links
Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
Date:8/20/2013

STOCKHOLM, August 20, 2013 /PRNewswire/ --

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).

     (Logo: http://photos.prnewswire.com/prnh/20130521/613959)

The trial is an open-label Phase II study designed to determine the level of efficacy of melflufen in combination with dexamethasone, for late stage, relapsing or relapsing/refractory patients. The primary end point is, best response in accordance with the International Myeloma Working Group criteria during up to eight cycles of treatment.

The trial is being carried out across four centers in Europe (the Netherlands, Italy, Denmark and Sweden) and two in the USA.

Chief Medical Officer Dr Johan Harmenberg commented, "Cytotoxic compounds form an integral part of combination treatment in malignant disease. Melphalan is part of the standard of care in multiple myeloma and improving this component with melflufen should result in significant patient benefit."

Multiple myeloma is the second most common hematological cancer and manifests from an abnormality of plasma cells, usually in the bone marrow. Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually (International Agency for Research on Cancer).

About Oncopeptides AB

Oncopeptides is a clinical stage pharmaceutical development company working to enhance oncology therapies, by creating cytosuperiors of existing basic cytotoxic compounds.

Oncopeptides is targeting multiple myeloma as a first indication with its lead compound, named melflufen which is a cytosuperior of the chemotherapeutic alkylator melphalan.

A family of enzymes that is overexpressed at very high levels in cancer cells, such as multiple myeloma cells, cleaves melflufen so its active metabolite is entrapped at high concentrations within the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease.

Primary cancer cells from patients representing twenty different types of cancers have been studied, including multiple myeloma, with melflufen showing 50- to 100-fold higher anti-tumor potency over melphalan.

For further information please contact:

Jakob Lindberg CEO
Tel: +46(0)705-695-471
e-mail: jakob.lindberg@oncopeptides.se

Web: http://www.oncopeptides.se


'/>"/>
SOURCE Oncopeptides AB
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
2. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
5. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
8. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
9. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
Breaking Biology News(10 mins):